Cantor Fitzgerald reaffirmed their buy rating on shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) in a report published on Thursday. Cantor Fitzgerald currently has a $31.00 target price on the biotechnology company’s stock.

Several other research firms have also weighed in on HRTX. Jefferies Group LLC reaffirmed a buy rating on shares of Heron Therapeutics in a research note on Wednesday, August 16th. Northland Securities initiated coverage on Heron Therapeutics in a research note on Wednesday, September 27th. They issued an outperform rating and a $40.00 price objective on the stock. Noble Financial reaffirmed a buy rating and issued a $24.00 price objective on shares of Heron Therapeutics in a research note on Friday, October 6th. Zacks Investment Research raised Heron Therapeutics from a hold rating to a buy rating and set a $14.00 price objective on the stock in a research note on Wednesday, July 12th. Finally, BidaskClub downgraded Heron Therapeutics from a hold rating to a sell rating in a research report on Friday, August 18th. One analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the stock. The stock has an average rating of Buy and an average target price of $28.36.

Shares of Heron Therapeutics (NASDAQ:HRTX) traded up $0.50 during trading on Thursday, reaching $16.05. 806,710 shares of the company’s stock traded hands, compared to its average volume of 636,486. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.72 and a current ratio of 2.82.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.10. The business had revenue of $8.51 million during the quarter, compared to analyst estimates of $4.53 million. equities analysts anticipate that Heron Therapeutics will post -3.49 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/heron-therapeutics-inc-hrtx-receives-buy-rating-from-cantor-fitzgerald/1678598.html.

Institutional investors have recently bought and sold shares of the business. Legal & General Group Plc raised its position in shares of Heron Therapeutics by 13.9% during the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 1,098 shares during the last quarter. Quantbot Technologies LP raised its position in shares of Heron Therapeutics by 2,619.6% during the second quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock worth $172,000 after acquiring an additional 12,024 shares during the last quarter. HighTower Advisors LLC raised its position in shares of Heron Therapeutics by 11.4% during the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after acquiring an additional 1,700 shares during the last quarter. Tudor Investment Corp ET AL bought a new position in shares of Heron Therapeutics during the first quarter worth about $253,000. Finally, Voya Investment Management LLC raised its position in shares of Heron Therapeutics by 44.4% during the second quarter. Voya Investment Management LLC now owns 20,377 shares of the biotechnology company’s stock worth $282,000 after acquiring an additional 6,267 shares during the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.